Why have breast cancer mortality rates declined?

Journal of Cancer Policy

Volumn 5, Issue , 2015, Pages 8-17

  Narod, Steven A ^a,b   Iqbal, Javaid ^a   Miller, Anthony B ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Case fatality rate; Incidence rate; Mortality rate; Prevention and control; SEER program; Survival

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COMPUTER PROGRAM; DISEASE SURVEILLANCE; FEMALE; HEALTH PROGRAM; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL;

EID: 84940033154     PISSN: None     EISSN: 22135383     Source Type: Journal    
DOI: 10.1016/j.jcpo.2015.03.002     Document Type: Article

References (54)

1. DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014, 64:52-62.
2. Chu K.C., Smart C.R., Tarone R.E. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 1988, 80:1125-1132.
3. Blanks R.G., Moss S.M., McGahan C.E., Quinn M.J., Babb P.J. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. Br Med J 2000, 321:665-669.
4. Swedish Organised Service Screening Evaluation Group Reduction in breast cancer mortality from the organised service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomark Prev 2006, 15:52-56.
5. Kricker A., Høyer A.P., McCredie M., Porter L.A. Breast cancer in NSW women a shift in tumour size. Med J Aust 1995, 163:79-81.
6. Kalager M1, Zelen M., Langmark F., Adami H.O. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010, 363:1203-1210.
7. Autier P., Boniol M., Gavin A., Vatten L.J. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Br Med J 2011, 343:d4411.
8. Bleyer A., Welch H.G. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012, 367:1998-2005.
9. McGale P., Taylor C., Correa C., Cutter D., Duane F., et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014, 383:2127-2135. EBCTCG (Early Breast Cancer Trialists' Collaborative Group).
10. Darby S., McGale P., Correa C., Taylor C., Arriagada R., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378:1707-1716. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
11. Martin J.A., Hamilton B.E., Ventura S.J., Osterman M.J., Mathews T.J. Births: final data for 2011 National vital statistics reports 2013, vol 62 (no 1). National Center for Health Statistics, Hyattsville, MD.
12. U.S. Census Bureau "Most Children Younger Than Age 1 Are Minorities Census Bureau Reports" accessed on September 5 2014.
13. SEER cancer statistics review, 1975-2011 2014, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. N. Howlader, A.M. Noone, M. Krapcho, J. Garshell, D. Miller, S.F. Altekruse (Eds.).
14. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence - SEER 9 Regs Research Data, November 2013 Sub (1973-2011) - Linked To County Attributes - Total U.S., 1969-2012. http://www.seer.cancer.gov/.
15. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence - SEER 18 Regs Research Data, November 2013 Sub (1973-2011) - Linked To County Attributes - Total U.S., 1969-2012. http://www.seer.cancer.gov/.
16. Surveillance Research Program, National Cancer Institute SEER*Stat software, version 8.1.5. http://www.seer.cancer.gov/seerstat.
17. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Mortality - All COD, Aggregated With County, Total U.S. (1969-2010) - Linked To County Attributes - Total U.S., 1969. http://www.seer.cancer.gov/.
18. http://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/.
19. Miller A.B., Baines C.J., To T., Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 1992, 147:1477-1488.
20. Miller A.B., Wall C., Baines C.J., Sun P., To T., Narod S.A. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. Br Med J 2014, 348:g366.
21. Narod S. Reflections on screening mammography and the early detection of breast cancer. Curr Oncol 2014, 21:210-214.
22. Warner E., Messersmith H., Causer P., Eisen A., Shumak R., Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008, 148:671-679.
23. Lee C.H., Dershaw D.D., Kopans D., Evans P., Monsees B., Monticciolo D., et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Colloid Radiol 2010, 7:18-27.
24. Biller-Andorno N., Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 2014, 370:1965-1967.
25. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 2006, 295:2727-2741.
26. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin R.S., Cecchini J.N., Atkins, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010, 3:696-706.
27. Cuzick J., Sestak I., Bonanni B., Costantino J.P., Cummings S., DeCensi A., et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013, 381:1827-1834.
28. Davies C., Godwin J., Gray R., Clarke M., Cutter D., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
29. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002, 288:321-333. 2002/07/19 ed.
30. Ravdin P.M. Hormone replacement therapy and the increase in the incidence of invasive lobular cancer. Breast Dis 2008-2009, 30:3-8.
31. Narod S.A. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 2011, 8:669-676.
32. Narod S.A., Valentini A., Nofech-Mozes S., Sun P., Hanna W. Tumour characteristics among women with very low-risk breast cancer. Breast Cancer Res Treat 2012, 134:1241-1246.
33. Teegarden D., Romieu I., Lelièvre S.A. Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved?. Nutr Res Rev 2012, 25:68-95.
34. Chajès V., Romieu I. Nutrition and breast cancer. Maturitas 2014, 77:7-11.
35. van Gils C.H., Peeters P.H., Bueno-de-Mesquita H.B., Boshuizen H.C., Lahmann P.H., Clavel-Chapelon F., et al. Consumption of vegetables and fruits and risk of breast cancer. J Am Med Assoc 2005, 293:183-193.
36. Martin L.J., Li Q., Melnichouk O., Greenberg C., Minkin S., Hislop G., et al. A randomized trial of dietary intervention for breast cancer prevention. Cancer Res 2011, 71:123-133.
37. Kim E.H., Willett W.C., Colditz G.A., Hankinson S.E., Stampfer M.J., Hunter D.J., et al. Dietary fat and risk of postmenopausal breast cancer in a 20-year follow-up. Am J Epidemiol 2006, 164:990-997.
38. Wang J., Eliassen A.H., Spiegelman D., Willett W.C., Hankinson S.E. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II. Cancer Causes Control 2014, 25:819-827.
39. IARC Weight control and physical activity 2002, IARC Press, Lyon.
40. Institute of Medicine Breast cancer and the environment: a life course approach 2012, The National Academies Press, Washington, DC.
41. Terry P.D., Rohan T.E. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomark Prev 2002, 11(10 (Pt 1)):953-971.
42. Singletary K.W., Frey R.S., Yan W. Effect of ethanol on proliferation and estrogen receptor-alpha expression in human breast cancer cells. Cancer Lett 2001, 165:131-137.
43. Zhang S.M., Lee I.M., Manson J.E., Cook N.R., Willett W.C., Buring J.E. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007, 165:667-676.
44. Narod S.A. Alcohol and risk of breast cancer. J Am Med Assoc 2011, 306:1920-1921.
45. H.R. 1740 (111th): Breast Cancer Education and Awareness Requires Learning Young Act of 2009.
46. Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. New Engl J Med 1976, 294:405-410.
47. Baum M., Brinkley D.M., Dossett J.A., McPherson K., Patterson J.S., Rubens R.D., et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983, 2:450.
48. Fisher B., Anderson S., Tan-Chiu E., Wolmark N., Wickerham D.L., Fisher E.R., et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001, 19:931-942.
49. Levine M.N., Bramwell V.H., Pritchard K.I., Norris B.D., Shepherd L.E., Abu-Zahra H., et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998, 16:2651-2658.
50. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
51. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
52. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
53. Henderson I.C. Chemotherapy for metastatic disease. Breast diseases 1991, 604-665. J.B. Lippincott Company, Philadelphia, PA. 2nd ed. J.R. Harris, S. Hellman, I.C. Henderson (Eds.).
54. Hortobagyi G.N. Can we cure limited metastatic breast cancer?. J Clin Oncol 2002, 20:620-623.